Skip to main content

Table 4 Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).

From: 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008

  Univariate analysis Multivariate analysis
  HR* 95% CI P aHR 95% CI P
Sex       
   Boys 1 - - 1 - -
   Girls 1.1 0.7-1.5 0.72 1.0 0.7-1.4 0.88
Age at ART initiation       
   10 years and plus 1 - - 1 - -
   [5-10] years 0.8 0.5-1.4 0.49 0.9 0.5-1.5 0.70
   [3-5] years 0.6 0.3-1.2 0.15 0.9 0.5-1.7 0.68
   [1-3] years 1.5 0.9-2.6 0.12 1.2 0.7-2.1 0.40
   < 12 months 1.2 0.4-4.3 0.69 1.1 0.3-3.8 0.79
ART regimen at baseline       
   2 NRTI+1 NNRTI 1 - - 1   
   2 NRTI+1 PI 0.7 0.4-1.0 0.06 0.9 0.6-1.5 0.76
   Other 0.2 0.02-2.6 0.21 1.0 0.2-5.0 0.98
Clinical stage at ART initiation       
   A, B or I, II, III 1 - - 1 - -
   AIDS or IV 6.0 3.9-9.2 < 0.01 2.5 1.6-3.9 < 0.01
   Unknown 0.9 0.4-2.0 0.90 1.4 0.7-2.9 0.29
% CD4 at ART initiation       
   ≥ 15% 1 - - 1 - -
   < 15% 2.1 1.1-3.9 0.02 2.1 1.1-4.1 0.03
   Missing 1.5 0.7-3.3 0.22 1.5 0.6-3.6 0.27
Year of ART initiation       
   ≤ 2004 1 - - 1 - -
   2005 1.8 1.0-3.0 0.03 1.7 1.0-2.9 0.04
   ≥ 2006 2.6 1.7-4.2 < 0.01 2.8 1.7-4.7 < 0.01
Initiation of cotrimoxazole at ART initiation       
   No 1 - - 1 - -
   Yes 1.3 0.7-2.5 0.39 0.9 0.5-1.7 0.67
   Missing 0.6 0.1-3.1 0.50 0.4 0.1-2.3 0.30
  1. IeDEA paediatric West Africa database (pWADA), 2000-2007. Mortality analysis.
  2. *HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
  3. Heterogeneity between cohort, p = 0.25